Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000921895-26-000973
Filing Date
2026-04-13
Accepted
2026-04-13 19:56:12
Documents
2
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 14967
2 TRANSACTIONS IN SECURITIES ex1to13da314125002_041326.htm EX-1 11677
  Complete submission text file 0000921895-26-000973.txt   28530
Mailing Address 701 VETERANS CIRCLE WARMINSTER PA 18974
Business Address 701 VETERANS CIRCLE WARMINSTER PA 18974 604-419-3200
Arbutus Biopharma Corp (Subject) CIK: 0001447028 (see all company filings)

EIN.: 980597776 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-85963 | Film No.: 26858865
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 12 E. 49TH STREET 40TH FLOOR NEW YORK NY 10017
Business Address 12 E. 49TH STREET 40TH FLOOR NEW YORK NY 10017 2122594370
Whitefort Capital Management, LP (Filed by) CIK: 0001884931 (see all company filings)

EIN.: 820808818 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A